Theranostic chimeric antigen receptor (CAR)-T cells : Insight into recent trends and challenges in solid tumors
Copyright © 2023 Elsevier Inc. All rights reserved..
Cell therapy has reached significant milestones in various life-threatening diseases, including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor (CAR)-T cell is a successful strategy for diagnosing or treating malignancies. Since cell therapy approaches have different results in cancers, the success of hematological cancers has yet to transfer to solid tumor therapy, leading to more casualties. Therefore, there are many areas for improvement in the cell therapy platform. Understanding the therapeutic barriers associated with solid cancers through cell tracking and molecular imaging may provide a platform for effectively delivering CAR-T cells into solid tumors. This review describes CAR-T cells' role in treating solid and non-solid tumors and recent advances. Furthermore, we discuss the main obstacles, mechanism of action, novel strategies and solutions to overcome the challenges from molecular imaging and cell tracking perspectives.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:328 |
|---|---|
| Enthalten in: |
Life sciences - 328(2023) vom: 01. Sept., Seite 121917 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kheyrolahzadeh, Keyvan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive cell therapies |
|---|
| Anmerkungen: |
Date Completed 24.07.2023 Date Revised 24.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lfs.2023.121917 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359231209 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359231209 | ||
| 003 | DE-627 | ||
| 005 | 20231226080431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lfs.2023.121917 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359231209 | ||
| 035 | |a (NLM)37422069 | ||
| 035 | |a (PII)S0024-3205(23)00552-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kheyrolahzadeh, Keyvan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Theranostic chimeric antigen receptor (CAR)-T cells |b Insight into recent trends and challenges in solid tumors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.07.2023 | ||
| 500 | |a Date Revised 24.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Cell therapy has reached significant milestones in various life-threatening diseases, including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor (CAR)-T cell is a successful strategy for diagnosing or treating malignancies. Since cell therapy approaches have different results in cancers, the success of hematological cancers has yet to transfer to solid tumor therapy, leading to more casualties. Therefore, there are many areas for improvement in the cell therapy platform. Understanding the therapeutic barriers associated with solid cancers through cell tracking and molecular imaging may provide a platform for effectively delivering CAR-T cells into solid tumors. This review describes CAR-T cells' role in treating solid and non-solid tumors and recent advances. Furthermore, we discuss the main obstacles, mechanism of action, novel strategies and solutions to overcome the challenges from molecular imaging and cell tracking perspectives | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adaptive cell therapies | |
| 650 | 4 | |a CAR-T | |
| 650 | 4 | |a Cell therapies | |
| 650 | 4 | |a Cell tracking | |
| 650 | 4 | |a Molecular imaging | |
| 650 | 4 | |a Positron emission tomography | |
| 650 | 4 | |a Theranostic | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Tohidkia, Mohammad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Tarighatnia, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Shahabi, Parviz |e verfasserin |4 aut | |
| 700 | 1 | |a Nader, Nader D |e verfasserin |4 aut | |
| 700 | 1 | |a Aghanejad, Ayuob |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life sciences |d 1965 |g 328(2023) vom: 01. Sept., Seite 121917 |w (DE-627)NLM000007579 |x 1879-0631 |7 nnns |
| 773 | 1 | 8 | |g volume:328 |g year:2023 |g day:01 |g month:09 |g pages:121917 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lfs.2023.121917 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 328 |j 2023 |b 01 |c 09 |h 121917 | ||